Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

104 trials with published results (30%)

Research Maturity

236 completed trials (67% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

7.7%

27 terminated out of 352 trials

Success Rate

89.7%

+3.2% vs benchmark

Late-Stage Pipeline

28%

100 trials in Phase 3/4

Results Transparency

44%

104 of 236 completed with results

Key Signals

104 with results90% success27 terminated

Data Visualizations

Phase Distribution

301Total
Not Applicable (112)
Early P 1 (1)
P 1 (24)
P 2 (64)
P 3 (70)
P 4 (30)

Trial Status

Completed236
Recruiting32
Terminated27
Unknown26
Withdrawn12
Not Yet Recruiting8

Trial Success Rate

89.7%

Benchmark: 86.5%

Based on 236 completed trials

Clinical Trials (352)

Showing 20 of 20 trials
NCT06559306Phase 3RecruitingPrimary

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06785012Phase 2Active Not RecruitingPrimary

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

NCT07573176Phase 3RecruitingPrimary

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

NCT07227454Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

NCT06308653Phase 3Active Not RecruitingPrimary

Psilocybin for Major Depressive Disorder (MDD)

NCT07412756Phase 3RecruitingPrimary

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

NCT06511908Phase 2Recruiting

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

NCT05680727Phase 2CompletedPrimary

Individualized Functional Connectivity Targeting in aiTBS for Depression

NCT07258485CompletedPrimary

A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)

NCT07161492Not ApplicableNot Yet RecruitingPrimary

Brain Functional Connectivity Mechanism of Cognitive Flexibility Impairment and rTMS Intervention in Major Depressive Disorder

NCT06219681Not ApplicableTerminatedPrimary

Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression

NCT07618208Not Yet RecruitingPrimary

Student Precarity and Psychiatry

NCT06635135Phase 3TerminatedPrimary

A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure

NCT06558344Phase 2CompletedPrimary

A Study to Test Different Doses of BI 1569912 in People With Depression

NCT05232032Phase 2RecruitingPrimary

Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation

NCT05210153WithdrawnPrimary

Personalized Sertraline Dosing in Patients With Depression

NCT04533529Phase 3CompletedPrimary

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

NCT05915013Phase 1RecruitingPrimary

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

NCT04984512Phase 2RecruitingPrimary

The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder

NCT06860958Phase 3RecruitingPrimary

Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Scroll to load more

Research Network

Activity Timeline